Atossa Genetics (ATOS) Sees Large Volume Increase

Shares of Atossa Genetics Inc (NASDAQ:ATOS) saw an uptick in trading volume on Thursday . 10,322,604 shares traded hands during mid-day trading, an increase of 718% from the previous session’s volume of 1,261,392 shares.The stock last traded at $1.70 and had previously closed at $1.49.

A number of brokerages have recently weighed in on ATOS. ValuEngine upgraded Atossa Genetics from a “hold” rating to a “buy” rating in a report on Monday. Maxim Group reiterated a “buy” rating and issued a $5.00 price target on shares of Atossa Genetics in a report on Wednesday, January 9th.

Atossa Genetics (NASDAQ:ATOS) last announced its earnings results on Tuesday, November 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.01. As a group, equities analysts anticipate that Atossa Genetics Inc will post -5.13 EPS for the current fiscal year.

An institutional investor recently raised its position in Atossa Genetics stock. Virtu Financial LLC boosted its holdings in shares of Atossa Genetics Inc (NASDAQ:ATOS) by 405.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 69,903 shares of the company’s stock after purchasing an additional 56,064 shares during the quarter. Virtu Financial LLC owned about 1.24% of Atossa Genetics worth $71,000 at the end of the most recent quarter. 11.06% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at

Atossa Genetics Company Profile (NASDAQ:ATOS)

Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.

Recommended Story: Understanding Market Liquidity

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit